Kineta Inc.’s Novel Antiviral Compounds Inhibit Broad Array Of Emerging And Current Viruses Including Ebola

WASHINGTON--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, today presented encouraging pre-clinical animal and in vitro data from a novel class of molecules discovered by Kineta which inhibit diverse viral pathogens including Ebola, influenza A & B, dengue, West Nile, Lassa fever, respiratory syncytial virus and human coronaviruses. The results presented at the 7th International Symposium on Filoviruses showed these new molecules function by triggering host innate antiviral immunity rather than focusing on a specific viral target.

Help employers find you! Check out all the jobs and post your resume.